We polled infectious disease specialists about cryptococcal antigen screening for patients initiating HIV antiretroviral therapy. Of 215 respondents, 33% reported typically obtaining screening for patients with CD4 counts <200 cells/mm3 and 63% for counts <100 CD4 cells/mm3. Uncertainty about cryptococcal antigen screening benefits and recommendations suggests opportunities for education and increased screening.
Keywords: Cryptococcus; HIV; HIV/AIDS and other retroviruses; United States; antigen; cryptococcosis; diagnosis; fungi; surveys and questionnaires.